An Unexpected Diagnosis of Second Primary Malignancy in a Breast Cancer Survivor: A Case Report

Background: Breast cancer survival rates are increasing more than ever with the development of better diagnostic and therapeutic techniques. Survivors of breast cancer have an increased risk of developing second primary malignancies, which may be mistaken for breast cancer recurrence and lead to delayed diagnosis and poor prognosis. Case report: We report a case of a 62-year-old female who presented with shortness of breath and bone pain. She had a history of left triple-positive invasive ductal carcinoma (T1N0M0) treated with bilateral skin-sparing mastectomy, adjuvant Taxotere, and trastuzumab-based therapy and then continued on trastuzumab and letrozole. She underwent imaging to explore the source of her symptoms at which new pulmonary nodules were discovered. During workup, she was found to have elevated tumor markers. They were initially suspected to be breast cancer recurrence metastases based on elevated tumor markers; however, further investigations confirmed that the nodules were a second primary lung adenocarcinoma with a different molecular profile. The patient had disease progression despite chemotherapy and eventually succumbed to her disease. Conclusion: This case highlights the importance of considering second primary malignancies in breast cancer survivors and utilizing advanced diagnostic modalities to efficiently diagnose such cases.

[1]  G. Che,et al.  Authors' Reply to Letter to the Editor Regarding the Article "Risk and Influencing Factors for Subsequent Primary Lung Cancer After Treatment of Breast Cancer: A Systematic Review and Two Meta-Analyses Based on Four Million Cases". , 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[3]  A. Jemal,et al.  Breast Cancer Statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[4]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[5]  G. Che,et al.  Primary Lung Cancer After Treatment for Breast Cancer , 2021, International journal of women's health.

[6]  F. Cappuzzo,et al.  Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis , 2021, Molecular diagnosis & therapy.

[7]  David R. Jones,et al.  Primary lung cancer in women after previous breast cancer , 2021, BJS open.

[8]  Q. Wen,et al.  Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma , 2020, Thoracic cancer.

[9]  M. Tiemann,et al.  Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors , 2020, BMC Cancer.

[10]  A. Fakhari,et al.  Correlation of cancer antigen 15-3 (CA15-3) serum level and bony metastases in breast cancer patients , 2019, Medical journal of the Islamic Republic of Iran.

[11]  N. Hulikal,et al.  Metachronous Second Primary Malignancies in Known Breast Cancer Patients on 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography–Computerized Tomography in a Tertiary Care Center , 2019, Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India.

[12]  Y. Shu,et al.  Second Primary Lung Cancer After Breast Cancer: A Population-Based Study of 6,269 Women , 2018, Front. Oncol..

[13]  P. Malmström,et al.  Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen , 2017, Acta oncologica.

[14]  S. Armato,et al.  Clinical significance of noncalcified lung nodules in patients with breast cancer , 2016, Breast Cancer Research and Treatment.

[15]  Christopher I. Li Abstract ES5-2: Second primary cancers among breast cancer survivors: Incidence and risk factors , 2015 .

[16]  A. Berrington de González,et al.  The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status , 2012, Cancer Causes & Control.

[17]  J. Stebbing,et al.  The clinical significance of radiologically detected silent pulmonary nodules in early breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  J. Siegfried,et al.  Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. , 2005, Cancer research.

[19]  A. Dasgupta,et al.  Diagnostic Role of Tumour Markers CEA, CA15-3, CA19-9 and CA125 in Lung Cancer , 2012, Indian Journal of Clinical Biochemistry.

[20]  Matthew J Hayat,et al.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. , 2007, The oncologist.